|
|
|
| Feasibility analysis of glucocorticoid in the treatment of severe heart failure |
| HUANG Zhong-yi |
| Department of Emergency,Shenzhen Hospital,Southern Medical University,Guangdong Province,Shenzhen 518100,China |
|
|
|
|
Abstract Objective To investigate the clinical efficacy of glucocorticoids in the treatment of severe heart failure with Irbesartan and Hydrochlorothiazide.Methods 50 patients with severe heart failure treated in our hospital from January 2016 to July 2017 were selected as subjects and randomly divided into control group and study group according to random number method,25 cases in each group.The patients in the control group were treated with Irbesartan and Hydrochlorothiazide,and patients in the the study group were treated with glucocorticoids combined with Irbesartan and hydrochlorothiazide.The clinical efficacy,echocardiographic findings,changes of neuroendocrine factors and the distance of 6 min walk test were compared between the two groups.Results The total effective rate of the study group (92.00%)was significantly higher than that of the control group(70.00%),and the difference was statistically significant(P＜0.05).After the intervention,two groups of LVISD,LVIDD,LVEDV and LVESV both were significantly lower than before the intervention,LVEF was significantly higher than before the intervention,and the differences were statistically significant(P＜0.05).The LVISD,LVIDD,LVEDV and LVESV in the study group were significantly lower than those in the control group,LVEF was significantly higher than that in the control group,and the differences were statistically significant(P＜0.05).After the intervention,two groups of ALD,COR,ET,TGF-Β1and Hs-CRP both were compared,and the differences were statistically significant(P＜0.05),while the ANP and Β2-MG were compared,the differenced were not statistically significant(P＞0.05).After the intervention,the distance of 6 min walking test in the study group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion Glucocorticoid-assisted Irbesartan and Hydrochlorothiazide in the treatment of severe heart failure can improve neuroendocrine factor secretion and cardiac function and improves clinical efficacy.
|
|
|
|
|
|
| [1] |
翟向伟.厄贝沙坦氢氯噻嗪结合低剂量甲状腺素治疗老年重症心力衰竭的临床疗效分析[J].陕西医学杂志，2015，44（9）：1191-1192.
|
| [2] |
李尚俭，陈新义.糖皮质激素辅助治疗慢性心力衰竭的疗效及其对神经体液因子影响的研究[J].实用医学杂志，2005，21（9）：964-966.
|
| [3] |
毕立雄.老年重症心力衰竭患者采用厄贝沙坦氢氯噻嗪联合美托洛尔治疗的效果评价[J].云南医药，2015，36（6）：677-678.
|
| [4] |
张海燕，赵玉祥.厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭的疗效观察[J].中西医结合心血管病电子杂志，2015，3（21）：59.
|
| [5] |
李文格，郑民洁，杜怀文，等.厄贝沙坦氢氯噻嗪联合螺内酯治疗舒张性心力衰竭的疗效观察[J].兵团医学，2013，35（1）：1-3.
|
| [6] |
王欣昌.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].包头医学院学报，2016，32（4）：32-33.
|
| [7] |
周宇明.美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭疗效观察[J].现代中西医结合杂志，2015，24（10）：1092-1094.
|
| [8] |
顾德明.厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭的疗效研究[J].实用心脑肺血管病杂志，2014，22（5）：16-17.
|
| [9] |
陈侯君.厄贝沙坦氢氯噻嗪联合美托洛尔对老年重症心力衰竭疗效分析[J].深圳中西医结合杂志，2016，26（3）：91-93.
|
| [10] |
谢朝阳.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].齐齐哈尔医学院学报，2016，37（23）：2914-2915.
|
| [11] |
张静.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的观察[J].辽宁医学院学报，2016，37（2）：32-34.
|
| [12] |
甄宇治，邓彦东，刘超，等.糖皮质激素对重症心力衰竭患者神经内分泌因子影响的临床研究[J].中国全科医学，2012，15（1）：54-56.
|
| [13] |
黎辉.厄贝沙坦氢氯噻嗪联合糖皮质激素治疗重症心力衰竭患者临床疗效的研究[J].中国急救医学，2016，36（2）：130-133.
|
| [14] |
王远桥.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].北方药学，2015，26（3）：37.
|
| [15] |
魏新考，李亚昭，崔利锋.糖皮质激素辅助治疗对重症心力衰竭患者心功能及血浆皮质醇、脑钠肽的影响[J].医学综述，2017，23（3）：581-584.
|
| [16] |
陈顺洪.老年重症心力衰竭急诊内科治疗的临床分析[J].中外医学研究，2016，14（31）：152-153.
|
| [17] |
陈志乐，王小智，梁萍，等.血必净注射液治疗重症肺炎并心力衰竭患者对心功能及相关细胞因子分析[J].临床和实验医学杂志，2017，16（15）：1519-1522.
|
| [18] |
苏琴.:急性重症左心衰竭患者应用呼吸机治疗效果的初步评定及研究[J].中外医学研究，2016，14（8）：105-106.
|
| [19] |
文永虹.:重组人脑利钠肽联合低分子肝素钙治疗重症肺心病心力衰竭的效果[J].中国当代医药，2017，24（11）：38-40.
|
| [20] |
何映.急诊内科老年重症心力衰竭治疗方法探讨[J].中外医学研究，2017，15（2）：115-116.
|
|
|
|
